ArticleCureus2026
Assessing Treatment Outcomes of Chondromyxoid Fibroma: A Case Series.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChondromyxoid fibroma (CMF) is a rare, benign, and locally aggressive bone tumor. It presents diagnostic challenges due to its radiologic similarity to other lesions and variable recurrence rates following surgical treatment. Current literature lacks standardized treatment guidelines, and nonoperative management strategies have not been previously described.
methodsWe conducted a retrospective review of patients diagnosed with CMF at our institution between 2010 and 2024. Eight patients met the inclusion criteria, with treatment modalities including en bloc resection (n=2), intralesional curettage with adjuvants (n=4), and conservative management with serial imaging (n=2). Demographic, clinical, and treatment-related data were collected, and outcomes were analyzed.
resultsThe cohort consisted of three males and five females, with a mean age of 55.3 ± 11.8 years and an average follow-up of 41.7 ± 28.5 months (range: eight to 104 months). Lesions were located in the distal femur (n=3), pelvis (n=2), clavicle (n=1), great toe (n=1), and T3 vertebral body (n=1). All surgical patients remained free of tumor recurrence, regardless of treatment modality. Two patients (25%) treated with en bloc resection experienced surgical complications requiring revision arthroplasty. Conservative management with serial imaging was successful in two asymptomatic patients (25%), with no evidence of disease progression over eight and 104 months, respectively.
conclusionThis case series demonstrates that en bloc resection, intralesional curettage with adjuvants, and conservative management with serial imaging are viable options for managing CMF, depending on patient-specific factors. Notably, to the best of our knowledge, this is the first series to document successful nonoperative management of CMF with serial imaging in carefully selected asymptomatic patients. Our results add to the limited literature on CMF and propose that serial imaging could be a potential management strategy in select patients with CMF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.